医学
肺癌
脑转移
曲妥珠单抗
肿瘤科
内科学
癌症
癌症研究
疾病
转移
化疗
肺
中枢神经系统
免疫组织化学
临床试验
免疫疗法
单克隆抗体
癌
卡尔诺夫斯基绩效状态
病理
作者
Pasi A. Jänne,David Planchard,Kōichi Goto,Egbert F. Smit,Adrianus J. de Langen,Yasushi Goto,Kiichiro Ninomiya,Toshio Kubo,M. Pérol,Enriqueta Felip,Hidetoshi Hayashi,Kazuhiko Nakagawa,Junichi Shimizu,Misako Nagasaka,Kaline Pereira,Ayumi Taguchi,Ahmed Ali,Maha Karnoub,Rie Yonemochi,David Leung
出处
期刊:JAMA network open
[American Medical Association]
日期:2025-11-12
卷期号:8 (11): e2543107-e2543107
被引量:1
标识
DOI:10.1001/jamanetworkopen.2025.43107
摘要
In this secondary analysis, T-DXd at the approved dose of 5.4 mg/kg showed antitumor activity in patients with previously treated ERBB2-mutant metastatic NSCLC with or without brain metastases. This finding supports T-DXd 5.4 mg/kg use in this population.
科研通智能强力驱动
Strongly Powered by AbleSci AI